This randomized clinical trial assesses whether aspirin, prophylactic-dose apixaban, or therapeutic-dose apixaban, compared with placebo, can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable US outpatients with COVID-19.
This systematic review to support the 2021 US Preventive Services Task Force Recommendation Statement on aspirin use to prevent preeclampsia and related morbidity and mortality summarizes published evidence on the benefits and harms of aspirin use in individuals at increased preeclampsia risk based on clinical risk factors or measurements associated with higher disease incidence.
This 2021 Recommendation Statement from the US Preventive Services Task Force recommends the use of low-dose aspirin (81 mg/d) as preventive medication for preeclampsia after 12 weeks of gestation in persons at high risk for preeclampsia (B recommendation).
This JAMA Patient Page summarizes the US Preventive Services Task Force’s recent recommendations on using aspirin during pregnancy to prevent preeclampsia and preeclampsia-related complications.
This narrative review summarizes oral antiplatelet therapy and specifically addresses the effects of dual antiplatelet therapy for patients with acute coronary syndrome who have not taken anticoagulants.
You currently have no searches saved.
Create a personal account or sign in to: